Jincheng Tang

Jincheng Tang

Auto-generated profile, based on publicly available information

Jincheng Tang

Cancer Research Institute of Hunan Academy of Traditional Chinese Medicine, Hunan Academy of Traditional Chinese Medicine, Changsha, China

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1995 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
QTQ. Tian
Q. Tian
DZD. Zhao
D. Zhao
DTD. Y. Tan
D. Y. Tan
YZY. T. Zhao
Y. T. Zhao
QLQ. H. Li
Q. H. Li
JCJ. K. Chang
J. K. Chang
Human adrenomedullin (hADM) is a newly isolated peptide with hypotensive activity in normotensive rats. The objective of this study was to investigate the effect of hADM(13–52) on hypertensive animals. hADM(13–52) induced a dose-dependent decrease in the blood pressure of spontaneously hypertensive rats and renal hypertensive rats. This result suggests that hADM is a novel antihypertensive peptide. In isolated rat aortic arteries, hADM(13–52) produced nitric oxide dependent relaxation and inhibited endothelin 1 and angiotensin II release. These in vitro effects may represent the molecular mechanisms underlying the hypotensive action of hADM in vivo.Key words: human adrenomedullin, nitric oxide, endothelin 1, angiotensin II, hypertension.

15 August 2025 in Medicine
Verified
Journal Article
Open access
NTNing Tang
Ning Tang
JTJincheng Tang
Jincheng Tang
JZJingting Zhang
Jingting Zhang
HCHongyao Chen
Hongyao Chen
RYRenyi Yang
Renyi Yang
This study explores the causal relationship between plasma lipidome and 6 common cancers using Mendelian randomization. Genome-wide association study data on 179 lipid species were used as exposures, with genome-wide association study datasets for 6 cancers as outcomes. The primary method was inverse variance weighted analysis, supplemented by Mendelian randomization-Egger regression and weighted median approaches. Sensitivity analyses, including the Steiger test, were conducted to evaluate the directionality and robustness of the causal relationships. Key findings identified phosphatidylethanolamine (16:0_20:4) as a risk factor for hepatic cancer, while sphingomyelin (d40:1) was protective. For lung cancer, sterol ester (27:1/20:4) increased risk, whereas sterol ester (27:1/18:2) reduced it. Sterol ester (27:1/20:3) was a risk factor for colorectal cancer, while phosphatidylcholine (18:2_0:0) was protective. Phosphatidylcholine (16:0_20:4) increased esophageal cancer risk, while phosphatidylcholine (16:0_18:3) offered protection. Phosphatidylinositol (18:0_20:4) increased thyroid cancer risk, while phosphatidylinositol (16:0_18:2) was protective. Diacylglycerol (18:1_18:2) was protective against breast cancer. These findings shed light on the causal link between lipid metabolism and cancer risk, contributing to the understanding of lipid involvement in cancer pathogenesis and offering potential strategies for early detection and treatment.

1 October 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
XLXing Luo
Xing Luo
JTJincheng Tang
Jincheng Tang
WPWei Peng
Wei Peng
FLFang Liu
Fang Liu
Background: Elderly patients with metastatic colon cancer (CC) face a poor prognosis, and there is a critical lack of individualized survival prediction tools for this population. To address this gap, our study aimed to develop and validate a novel prognostic nomogram that integrates multiple clinical factors to accurately predict overall survival (OS) and guide treatment decisions. Methods: Patients aged over 60 years with pathologically confirmed metastatic CC were identified from the Surveillance, Epidemiology, and End Results (SEER) database (2010–2016). Univariate and multivariate logistic regression analyses were used to identify factors associated with distant metastasis (bone, brain, liver, lung). Patients were randomly assigned (1:1) into training and validation cohorts. OS was the primary endpoint. Prognostic factors were determined using Cox regression in the training cohort. A nomogram was developed based on independent predictors and validated using time-dependent ROC curves, calibration plots, and decision curve analysis (DCA). Results: A total of 6,851 elderly patients with metastatic CC were included. The median age was 70 years. Most patients received surgery (78%) and chemotherapy (66%). Twelve independent predictors of OS were identified, including age, tumor site, histologic grade, tumor-node-metastasis (TNM) stage, treatment strategies, carcinoembryonic antigen (CEA) level, and metastasis pattern. The nomogram demonstrated strong discriminatory ability with areas under the curves (AUCs) of 0.785, 0.786, and 0.795 for 1-, 3-, and 5-year OS in the training cohort, and 0.792, 0.784, and 0.793 in the validation cohort. Calibration curves showed good agreement between predicted and actual outcomes. DCA confirmed clinical utility. Patients were effectively stratified into low-, medium-, and high-risk groups based on nomogram scores. Conclusions: This internally validated nomogram provides reliable individualized survival predictions for elderly patients. It offers a practical tool to assist clinicians in optimizing treatment strategies and risk stratification for this vulnerable population.